Protagenic Therapeutics (PTIX) announced the appointment of Bill Nichols Jr. as President. At Protagenic, Nichols will drive integrated clinical development, corporate strategy, and enterprise planning as the Company prepares to initiate Phase 2 enrollment for PT00114 in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTIX:
- Protagenic Therapeutics Announces Termination of Chief Financial Officer
- Protagenic Therapeutics completes Phytanix separation
- Protagenic Therapeutics upgrades from OTC Pink to OTCQB Venture Market
- Protagenic Therapeutics Appoints William Nichols as President
- Protagenic Therapeutics Unwinds Phytanix Deal and Settles Litigation